Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study
The present study suggests the feasibility and efficacy of Neo-P DC vaccine therapy after surgical treatment of pancreatic cancer in both postoperative recurrence cases and adjuvant setting. A case analysis suggests the importance of combination with long peptides targeting CD4<sup>+</sup> T cell.
Authors
- Shinji Morisaki
- Toshiya Abe (ORCID: https://orcid.org/0000-0003-2148-4852)
- Kazuma Kiyotani (ORCID: https://orcid.org/0000-0002-9236-9061)
- Nao Fujimori (ORCID: https://orcid.org/0000-0003-4286-8804)
- Norihiro Koya
- Naoki Ikenaga
- Chika Iwamoto (ORCID: https://orcid.org/0000-0001-7139-325X)
- Kenta Tsujimura
- Koki Oyama (ORCID: https://orcid.org/0009-0001-8610-0277)
- Hideya Onishi
- Yusuke Nakamura (ORCID: https://orcid.org/0000-0002-5376-9513)
- Masayo Umebayashi
- Kento Hirotaka (ORCID: https://orcid.org/0000-0002-9062-4671)
- Sachiko Yoshimura
- Masafumi Nakamura (ORCID: https://orcid.org/0000-0002-5584-8311)
- Kohei Nakata (ORCID: https://orcid.org/0000-0002-5717-8569)
- Takashi Morisaki (ORCID: https://orcid.org/0009-0004-3642-1656)
- Hiroto Tanaka
- Shinichiro Nakagawa
Institutions
- Kyushu University (JP)
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Saiseikai Fukuoka General Hospital (JP)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.3389/fimmu.2025.1571182
- Citations
- 7
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 5.58